| Title |
A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, August 2009
|
| DOI | 10.1007/s00262-009-0746-z |
| Pubmed ID | |
| Authors |
Pina M. Cardarelli, Chetana Rao-Naik, Sharline Chen, Haichun Huang, Amie Pham, Maria-Cristina Moldovan-Loomis, Chin Pan, Ben Preston, David Passmore, Jie Liu, Michelle R. Kuhne, Alison Witte, Diann Blanset, David J. King |
| Abstract |
A human anti-CD19 antibody was expressed in fucosyltransferase-deficient CHO cells to generate nonfucosylated MDX-1342. Binding of MDX-1342 to human CD19-expressing cells was similar to its fucosylated parental antibody. However, MDX-1342 exhibited increased affinity for FcγRIIIa-Phe158 and FcγRIIIa-Val158 receptors as well as enhanced effector cell function, as demonstrated by increased potency and efficacy in antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis assays. MDX-1342 showed dose-dependent improvement in survival using a murine B-cell lymphoma model in which Ramos cells were administered systemically. In addition, low nanomolar binding to cynomolgus monkey CD19 and increased affinity for cynomolgus monkey FcγRIIIa was observed. In vivo administration of MDX-1342 in cynomolgus monkeys revealed potent B-cell depletion, suggesting its potential utility as a B-lymphocyte depletive therapy for malignancies and autoimmune indications. |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 3% |
| Unknown | 30 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 29% |
| Professor | 4 | 13% |
| Student > Ph. D. Student | 4 | 13% |
| Other | 3 | 10% |
| Student > Bachelor | 3 | 10% |
| Other | 4 | 13% |
| Unknown | 4 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 9 | 29% |
| Immunology and Microbiology | 5 | 16% |
| Medicine and Dentistry | 4 | 13% |
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Other | 3 | 10% |
| Unknown | 5 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2023.
All research outputs
#7,682,308
of 23,377,816 outputs
Outputs from Cancer Immunology, Immunotherapy
#1,050
of 2,925 outputs
Outputs of similar age
#37,970
of 112,597 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#5
of 15 outputs
Altmetric has tracked 23,377,816 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,925 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 112,597 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.